Cytokine Signalling Forum

Publications




Eficacia de Baricitinib en el Tratamiento de la Artritis Reumatoide: Efecto Modulatorio en Biomarcadores Inflamatorios y de Fibrose en un Escenario de Vida Real

Alessandro M, Perillo F, Refini R, Bergantini L, Bellisai F, Selvi E, Cameli P, Manganelli S, Conticini E, Cantarini L, Sestini P, Frediani B, Bargagli E. - Int Immunopharmacol. 2020 Sep;86:106748.

BARI demonstrated to be a safe immune modulator that reduces the concentrations biomarkers of lung fibrosis and inflammation in RA patients, including a subgroup with interstitial lung involvement. Professor Alessandro and colleagues analysed the effects of baricitinib in a population of RA and RA-ILD patients in a real-life setting, describing any changes in lung function parameters, serum inflammatory biomarkers and fibrotic biomarkers after 6 months of treatment.

Fifteen patients were recruited and eleven were treated with either 4 mg/day baricitinib monotherapy (11) or combination therapy (4) Patients were monitored for a period of six months, and were tested for lung function, adipokines, and for KL-6 concentration, which is expressed in the lung by regenerating or injured alveolar type II cells.

BARI decreased the systemic inflammation of RA by lowering expression of IL-6 and CRP and reducing ESR and serum concentrations of adiponectin. However, there was an increase in concentrations of proinflammatory adipokines (including, adipsin, resistin and leptin). Finally, KL-6 concentrations were reduced by BARI, which reflects the stability of interstitial lung involvement.

In conclusion, baricitinib was demonstrated to be a safe immune modulator that reduces the concentrations biomarkers of lung fibrosis and inflammation in RA patients, including a subgroup with interstitial lung involvement.

Keywords: JAK, Baricitinib, Clinical, Efficacy

Access original article via Pubmed

Upload date: October 2020

Translated by: Igor Kos

Article image